Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine) (457071-73-7)

Identification
Name:	Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine)
Synonyms:	Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine);N-(3-Butenyl)norbuprenorphine;Buprenorphine Related CoMpound A CII
CAS:	457071-73-7
Molecular Formula:	C29H41NO4
Molecular Weight:	467.64014
Molecular Structure:
Properties
Safety Data

Other Product

Drometrizole Trisiloxane Related Compound A (25 mg) (2-(2H-Benzotriazol-2-yl)-6-(isobuten-1-yl)-p-cresol)
NABUMETONE RELATED COMPOUND A (15 MG) (1-(6-METHOXY-2-NAPHTHYL)-BUT-1-EN-3-ONE)
1/C22H28O6/c1-23-17-11-21(27-5)19(25-3)9-15(17)13-7-8-14(13)16-10-20(26-4)22(28-6)12-18(16)24-2/h9-14H,7-8H2,1-6H3/t13-,14
Salmeterol Related Compound B (10 mg) (4-{1-Hydroxy-2-[6-(4-phenylbutan-2-yloxy)hexylamino]ethyl}-2-(hydroxymethyl)phenol)
1/C21H26N2O4/c1-3-14-8-9-19(25)23(12-14)11-10-16-15-6-4-5-7-18(15)22-20(16)17(13-24)21(26)27-2/h4-7,12,17,22,24H,3,8-11,13H2,1-2H
Anagrelide Related Compound A (25 mg) (ethyl 2-(6-amino-2,3-dichlorobenzylamino)acetate)
1/C26H18O2/c1-17-16-23-21-9-5-3-7-19(21)11-13-25(23)28-26(17)15-14-22-20-8-4-2-6-18(20)10-12-24(22)27-26/h2-16H,1H
Citalopram Related Compound H (25 mg) (1-(4'-fluorophenyl)-1-(3-dimethylaminopropyl)-5-bromophthalane hydrobromide)
FENOFIBRATE RELATED COMPOUND C (25 MG) (1-METHYLETHYL 2-[[2-[4-(4-CHLOROBENZOYL)PHENOXY]-2-METHYLPROPANOYL]OXY]-2-METHYLPROPANOATE)
1/C19H15ClN2O2S/c1-11-19(23)24-17-18(25-11)22(2)15-9-8-13(20)10-14(15)16(21-17)12-6-4-3-5-7-12/h3-11H,1-2H
ETODOLAC RELATED COMPOUND A (25 MG) ((+/-)-8-ETHYL-1-METHYL-1,3,4,9-TETRAHYDROPYRANO [3,4-B]-INDOLE-1-ACETIC ACID)
1/C23H22N2O2/c26-23(27-22-15-25-11-7-17(22)8-12-25)21-14-18(13-16-5-9-24-10-6-16)19-3-1-2-4-20(19)21/h1-6,9-10,13-14,17,22H,7-8,11-12,15H2/b18-13
WARFARIN RELATED COMPOUND A (50 MG) (3-(O-HYDROXYPHENYL)-5-PHENYL-2-CYCLOHEXEN-1-ONE)
REPAGLINIDE RELATED COMPOUND C (25 MG) ((S)-2-ETHOXY-4-[2-[[2-PHENYL-1 -[2-(1 -PIPERIDINYL)PHE-NYL]ETHYL]AMINO]-2-OXOETHYL] BENZOIC ACID)
Doxepin Related Compound C (25 mg) ((E-3-(dibenzo[b,e]oxepin-11(6H)-ylidene)-N-methylpropan-1-amine hydrochloride)
Tenofovir Disoproxil Related Compound B (10 mg) ((E)-9-(Prop-1-enyl)-9H-purin-6-amine)
1/C27H27N3O3S/c1-30-25(20-11-15-23(33-3)16-12-20)24(19-9-13-22(32-2)14-10-19)29-27(30)34-18-17-28-26(31)21-7-5-4-6-8-21/h4-16H,17-18H2,1-3H3,(H,28,31
1/C17H16N2O3/c1-9(20)12-8-14-15-11(6-7-19(14)17(22)16(12)21)10-4-2-3-5-13(10)18-15/h2-5,8-9,18,20-21H,6-7H2,1H
Spiro[cyclopentane-1,2'-[9,4](epoxypentadeca[1,11,13]trienimino)[2H]furo[2',3':7,8]naphth[1,2-d]imidazole]-10',26'(9'H)-dione,16'-(acetyloxy)-1',3'-dihydro-5',6',18',20'-tetrahydroxy-14'-methoxy-7',9',15',17',19',21',25'-heptamethyl-,[9'S-(9'R*,12'E,14'R*,15'S*,16'R*,17'S*,18'S*,19'S*,20'R*,21'R*,22'E,24'Z)]-(9CI)
Spiro[cyclohexane-1,2'-[9,4](epoxypentadeca[1,11,- 13]trienimino)[2H]furo[2',3':7,8]naphth[1,2-d]- imidazole]-10',26'(9'H)-dione,16'-(acetyloxy)- 1',3'-dihydro-5',6',18',20'-tetrahydroxy-14'- methoxy-7',9',15',17',19',21',25'-heptamethyl-,(9'S,12'E,14'S,15'R,16'S,17'R,18'R,19'R,20'S,- 21'S,22'E,24'Z)-